Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million

Reuters03-24

Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million

Sutro published a Form 10-K and press release reporting full-year 2025 results, with revenue of USD 102.5 million, up 65.2% on Astellas and Ipsen collaboration activity.
Operating expenses were USD 260.9 million, down 13.2%, while net loss was USD 191.1 million, narrowing 16%.
Cash, cash equivalents and marketable securities totaled USD 141.4 million, down 55.4%.
Gross proceeds of USD 110.0 million from an underwritten common stock offering extended expected cash runway into at least the second quarter of 2028.
Jane Chung said the company completed dosing the third cohort in the Phase 1 STRO-004 trial and expects initial clinical data in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9676941) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621814270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621814270","market":"us","top_or_hot":-1,"title":"Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sutro published a Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> and press release reporting full-year 2025 results, with revenue of USD 102.5 million, up 65.2% on Astellas and Ipsen collaboration activity.\n        </li>\n<li>\n          Operating expenses were USD 260.9 million, down 13.2%, while net loss was USD 191.1 million, narrowing 16%.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 141.4 million, down 55.4%.\n        </li>\n<li>\n          Gross proceeds of USD 110.0 million from an underwritten common stock offering extended expected cash runway into at least the second quarter of 2028.\n        </li>\n<li>\n          Jane Chung said the company completed dosing the third cohort in the Phase 1 STRO-004 trial and expects initial clinical data in mid-2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9676941) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sutro published a Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> and press release reporting full-year 2025 results, with revenue of USD 102.5 million, up 65.2% on Astellas and Ipsen collaboration activity.\n        </li>\n<li>\n          Operating expenses were USD 260.9 million, down 13.2%, while net loss was USD 191.1 million, narrowing 16%.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 141.4 million, down 55.4%.\n        </li>\n<li>\n          Gross proceeds of USD 110.0 million from an underwritten common stock offering extended expected cash runway into at least the second quarter of 2028.\n        </li>\n<li>\n          Jane Chung said the company completed dosing the third cohort in the Phase 1 STRO-004 trial and expects initial clinical data in mid-2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9676941) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL1tQjqs:1","article_id":"2621814270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621814270","pubTimestamp":1774296407,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sutro published a Form 10-K and press release reporting full-year 2025 results, with revenue of USD 102.5 million, up 65.2% on Astellas and Ipsen collaboration activity.Operating expenses were USD 260.9 million, down 13.2%, while net loss was USD 191.1 million, narrowing 16%.Cash, cash equivalents and marketable securities totaled USD 141.4 million, down 55.4%.Gross proceeds of USD 110.0 million from an underwritten common stock offering extended expected cash runway into at least the second quarter of 2028.Jane Chung said the company completed dosing the third cohort in the Phase 1 STRO-004 trial and expects initial clinical data in mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","STRO":"Sutro Biopharma Inc","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Sutro Biopharma 2025财年收入增长65.2%至1.02亿美元，净亏损收窄至1.91亿美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"STRO":0.9},"content_text":"Sutro Biopharma FY 2025 revenue rises 65.2% to USD 102 million, net loss narrows to USD 191 million\n    \n\n\n          Sutro published a Form 10-K and press release reporting full-year 2025 results, with revenue of USD 102.5 million, up 65.2% on Astellas and Ipsen collaboration activity.\n        \n\n          Operating expenses were USD 260.9 million, down 13.2%, while net loss was USD 191.1 million, narrowing 16%.\n        \n\n          Cash, cash equivalents and marketable securities totaled USD 141.4 million, down 55.4%.\n        \n\n          Gross proceeds of USD 110.0 million from an underwritten common stock offering extended expected cash runway into at least the second quarter of 2028.\n        \n\n          Jane Chung said the company completed dosing the third cohort in the Phase 1 STRO-004 trial and expects initial clinical data in mid-2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9676941) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621814270","isCrawlerRequest":true}